Advertisement

ASCO 2023: Osimertinib for Patients With EGFR-Mutated NSCLC
Posted: 06/20/2023 | By: Melissa E. Fryman, MS

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Herbst et al presented final overall survival results of the ADAURA trial, which evaluated the efficacy of osimertinib among patients with completely resected; EGFR-mutated; stage IB, II, or IIIA non–small cell lung cancer (NSCLC) (Abstract LBA3).

Question 1 of 5

Eligible patients in this study had completely resected EGFR-mutated stage IB, II, or IIIA NSCLC, and receipt of adjuvant chemotherapy was allowed. What kind of EGFR mutation did the patients enrolled in ADAURA have?

Choose 1

A
Exon 19 deletions/L858R point mutations
B
Exon 20 insertions
C
T790M-like mutations
D
PACC mutations

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage